HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide.

AbstractBACKGROUND AND PURPOSE:
NO is a vasodilator and independent modulator of cardiac remodelling. Commonly, in cardiac disease (e.g., heart failure), endothelial dysfunction (synonymous with NO deficiency) has been implicated in increased BP, cardiac hypertrophy and fibrosis. Currently, no effective therapies replacing NO have succeeded in the clinic. Inorganic nitrate (NO3 - ), through chemical reduction to nitrite and then to NO, exerts potent BP lowering, but whether it might be useful in treating undesirable cardiac remodelling is not known.
EXPERIMENTAL APPROACH:
We analysed demographics in a nested age- and sex-matched case-control study of hypertensive patients with or without left ventricular hypertrophy (NCT03088514) and assessed the effects of dietary nitrate in mouse models of cardiac dysfunction.
KEY RESULTS:
Lower plasma nitrite concentrations and vascular dysfunction accompanied cardiac hypertrophy and fibrosis in patients. In mouse models of cardiac remodelling, restoration of circulating nitrite levels using dietary nitrate improved endothelial dysfunction through targeting the xanthine oxidoreductase-driven increase in levels of H2 O2 and superoxide, and decreased cardiac fibrosis through NO-mediated block of SMAD phosphorylation leading to improvements in cardiac structure and function.
CONCLUSIONS AND IMPLICATIONS:
Dietary nitrate offers easily translatable therapeutic options for delivery of NO and thereby treatment of cardiac dysfunction.
AuthorsLorna C Gee, Gianmichele Massimo, Clement Lau, Christopher Primus, Daniel Fernandes, Jianmin Chen, Krishnaraj S Rathod, Alexander J P Hamers, Federica Filomena, Gani Nuredini, Abdiwahab Shidane Ibrahim, Rayomand S Khambata, Ajay K Gupta, James C Moon, Vikas Kapil, Amrita Ahluwalia
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 179 Issue 20 Pg. 4757-4777 (10 2022) ISSN: 1476-5381 [Electronic] England
PMID34309015 (Publication Type: Journal Article)
Copyright© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Chemical References
  • Nitrates
  • Nitrites
  • Vasodilator Agents
  • Superoxides
  • Nitric Oxide
  • Xanthine Dehydrogenase
Topics
  • Animals
  • Cardiomegaly (drug therapy)
  • Case-Control Studies
  • Clinical Studies as Topic
  • Disease Models, Animal
  • Fibrosis
  • Heart Failure (drug therapy)
  • Humans
  • Mice
  • Nitrates (pharmacology)
  • Nitric Oxide
  • Nitrites
  • Superoxides
  • Vasodilator Agents (therapeutic use)
  • Ventricular Remodeling
  • Xanthine Dehydrogenase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: